POSTER LISTING
*current as of May 18, 2023

PROFFERED TALKS

POSTER SESSION A

POSTER SESSION B
**Proffered Talks**

*current as of May 18, 2023*

**PR001, A018** Biorepository of clear cell and non-clear cell renal cell tumoroids to study unique therapeutic vulnerabilities. Samir Zaidi, Memorial Sloan Kettering Cancer Center, New York, New York.

**PR002, A015** Injury-associated transcriptional state transitions in early renal carcinogenesis. Sakari Vanharanta, University of Helsinki, Helsinki, Finland.

**PR003, A028** PBRM1-deficient PBAF complexes target aberrant genomic loci to activate NF-κB pathway in clear cell renal cell carcinoma. Xiaosai Yao, Genentech, South San Francisco, California.

**PR004, B021** Comparative genomic analysis of novel translocation renal cell carcinoma model reveals molecular mechanisms of disease progression and therapeutic opportunities. Gopinath Prakasam, UT Southwestern Medical Center, Dallas, Texas.

**PR005, B011** An atlas of cellular heterogeneity in primary and metastatic renal cell carcinomas. Ariel Madrigal, McGill University, Montreal Quebec, Canada.

**PR006, A004** STING is a vulnerability in RCC independent of its innate immunity function. Pengda Liu, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

**PR007, A010** Von Hippel Lindau (VHL) tumor suppressor regulates m6A-dependent gene expression involved in renal tumorigenesis. Cheng Zhang, UT Southwestern Medical Center, Dallas, Texas.

**PR008, B007** The SLC1A1/EAAT3 dicarboxylic amino acid transporter: An actionable, HIF-independent, hub that links epigenetic dysregulation to nucleotide metabolism in kidney cancer. Abhishek A. Chakraborty, Cleveland Clinic, Cleveland, Ohio.

**PR009, A025** Linking VHL and SETD2 in a common oncogenic pathway that converges on the mitotic spindle. Ruhee Dere, Baylor College of Medicine, Houston, Texas.

**PR010, A022** In-“speck”-ting the nucleus: Nuclear speckles are a critical layer of gene regulation that predict outcomes in clear cell renal cell carcinoma. Katherine A. Alexander, University of Pennsylvania, Philadelphia, Pennsylvania.

**PR011, A007** Downregulation of the HIF2a target Cyclin D1 underlies the efficacy of the HIF2a inhibitor Belzutifan in kidney cancer. Nitin H. Shirole, Dana Farber Cancer Institute, Boston, Massachusetts.

**PR012, B016** SETD2 safeguards the genome against isochromosome formation. Frank M. Mason, Vanderbilt University Medical Center, Nashville, Tennessee.

**PR013, B024** An integrative genomics approach converges on a critical OXPHOS program driven by MiT/TFE fusions in translocation renal cell carcinoma. Srinivas R. Viswanathan, Dana-Farber Cancer Institute, Boston, Massachusetts.
Macrophage induced epithelial to mesenchymal transition in sarcomatoid renal cell carcinoma. Allison May, University of Michigan, Ann Arbor, Michigan.

Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinoma. David A. Braun, Yale School of Medicine, New Haven, Connecticut.

Systemic T cell metabolic and effector function changes following treatment with PD1 and CTLA4 in patients with kidney cancer. Kathryn Beckermann, Vanderbilt University Medical Center, Nashville, Tennessee.
Poster Session A
Sunday, June 25
6:00-8:00 p.m.
*current as of May 18, 2023

A001 Targeting GPNMB in renal tumors in tuberous sclerosis complex and translocation renal cell carcinoma. Kaushal Asrani, Johns Hopkins Medicine, Baltimore, Maryland.

A002 Targeting Hypoxia Inducible Factor (HIF)-2α with AB521, a novel and potent small molecule HIF-2α inhibitor, for the treatment of clear cell renal cell carcinoma. Paul Foster, Arcus Biosciences, Hayward, California.

A003 Kinome-wide siRNA screening identifies DCLK2 as a TBK1 activator and therapeutic target for ccRCC. Lianxin Hu, UT Southwestern Medical Center, Dallas, Texas.

A005 Regulation of HHLA2 expression in renal cell carcinoma and myeloid cells. Kathleen Mahoney, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

A006 Identification of a potential lymphatic progenitor cell population in Vhlh conditional knockout mouse and in ccRCC tissue. Tuong-Vi Nguyen, National Central University, Taoyuan, Taiwan (Greater China).


A009 Therapeutic targeting of P2X4 receptor and mitochondrial metabolism in clear cell renal carcinoma. Sabrina Orsi, University at Buffalo, Buffalo, New York.

A011 Single-cell RNA sequencing reveals a potential renal tumor progenitor in conditional Vhlh knockout mouse model and ccRCC clinical samples. Dinh-Xuan Pham, College of Health Sciences and Technology, National Central University, Taoyuan City, Taiwan (Greater China).

A012 Investigating the heterogeneity and clinical significance of tumor-associated macrophages in renal cell carcinoma milieu. Evelyn M. Zavacky, McGill University, MontrealQuebec, Canada.

A014 Modeling recurrent chromosomal alterations in renal cell carcinoma evolution. Rashmi Dahiya, UT Southwestern Medical Center, Dallas, Texas.

A016 Elucidating the role of regulatory T cell in sarcomatoid clear cell renal cell carcinoma response to immunotherapy in humans and a novel mouse model. Hui Jiang, Memorial Sloan Kettering Cancer Center, New York, New York.

A017 Modeling metastatic latency and relapse. Srinivas Malladi, UT Southwestern Medical Center, Dallas, Texas.
A019 Development and characterization of novel pre-clinical models of SFPQ-TFE3-driven renal cell carcinoma. Adrianna Amaral de Aragao Mendes, Johns Hopkins University, Baltimore, Maryland.

A020 Calcitonin receptor-like receptor is expressed in blood vessels in clear cell renal cell carcinoma and upregulated in endothelial cells co-cultured with tumor cells. Matthew A. Morfitt, University of Hull, Kingston-upon-Hull, United Kingdom.

A021 Cell competition shapes metastatic latency and relapse. Kangsan Kim, UT Southwestern Medical Center, Dallas, Texas.


A024 Development of potent and selective nicotinamide N-methyltransferase inhibitors for kidney cancer. Rong Huang, Purdue University, West Lafayette, Indiana.

A026 Overactivation of histone deacetylases and EZH2 in Wilms tumorigenesis. Hongbing Liu, Tulane University, New Orleans, Louisiana.


A029 Epigenomic profiling nominates master transcription factors (TFs) driving sarcomatoid differentiation of renal cell carcinoma (RCC). Karl Semaan, Dana-Farber Cancer Institute, Boston, Massachusetts.
Poster Session B
Monday, June 26
5:00-7:00 p.m.

*current as of May 18, 2023


B002 Mitochondrial metabolism in primary and metastatic human kidney cancers. Divya Bezwada, UT Southwestern Medical Center, Dallas, Texas.


B004 Serine promotes invasive phenotype through enhanced translation of SNAIL in ccRCC. Suman Karki, University of Alabama at Birmingham, Birmingham, Alabama.

B005 Metabolic liabilities in high L-2HG kidney cancer. Anirban Kundu, University of Alabama at Birmingham, Birmingham, Alabama.

B006 Dissecting metabolic alterations of clear cell renal cell carcinomas one cell at a time. Lucas A. Salas, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.


B009 Isolating human RCC tumor cells details evolutionary relationships between cancer cell subsets and a role of OXPHOS in disease progression. Ewelina Sobierajska, Emory University, Atlanta, Georgia.

B010 Germline susceptibility to renal cell carcinoma and implications for genetic screening. Kate I. Glennon, McGill University, MontrealQuebec, Canada.

B012 Single-cell and spatial transcriptomic mapping of human renal cell carcinoma brain metastases uncovers actionable immune-resistance targets. Elshad Hasanov, The University of Texas MD Anderson Cancer Center, Houston, Texas.

B013 T cell clonotype expansion is common in advanced renal cell carcinoma but is not associated with altered response to PD-1 blockade. Miya Hugaboom, Yale School of Medicine, New Haven, Connecticut.

B014 Clonal neoantigens and tertiary lymphoid structures drive exceptional responses to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma. Tejas R. Jammihal, The University of Texas MD Anderson Cancer Center, Houston, Texas.

B017 SETD2-loss mediated H3K36me3 causes disruptions in topologically associated domains (TADs) to promote oncogenic expression in clear cell renal cell carcinoma. Amrita M Nargund, Memorial Sloan Kettering Cancer Center, New York, New York.

B019 Clinical and molecular characterization of chromophobe renal cell carcinoma: A focus on immunotherapy based regimens and the tumor immune microenvironment. Michel Alchoueiry, Brigham and Women's Hospital, Boston, Massachusetts.

B020 A mechanistic study of the TFE3-splicing machinery gene fusions reveals a new druggable target for translocation renal cell carcinoma. Ilaria Delle Fontane, University at Buffalo, Buffalo, New York.

B022 Clinical outcomes in NF2-mutated RCC treated with contemporary immunotherapy regimens. Kelly N. Fitzgerald, Memorial Sloan Kettering Cancer Center, New York, New York.

B023 Using hypoxia to improve tumor infiltrating lymphocytes therapy in different subtypes of renal cell carcinoma. Marine Potez, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

B025 Assessing therapeutic approaches for renal cell carcinoma via multispectral optoacoustic tomography. Li Liu, UT Southwestern Medical Center, Dallas, Texas.

B026 Combined inhibition of mammalian target of rapamycin (mTOR) and survivin augments radiation therapy in renal cell carcinoma. Krishnendu Pal, Mayo Clinic, Jacksonville, Florida.

B028 Tipifarnib synergizes with axitinib in renal cell carcinoma models. Jovylyn Gatchalian, Kura Oncology, San Diego, California.

B029 Tumor immune microenvironment determinants of response to Lenvatinib and a PD-1 blockade in clear cell renal cell carcinoma. Lynda Vuong, Memorial Sloan Kettering Cancer Center, New York, New York.

B030 Form and function in intratumoral immune organization: understanding the cellular composition of TCF1+ CD8+ T cell niches in human cancer. Caroline S. Jansen, Emory University School of Medicine, Atlanta, Georgia.

B031 Effect of macrophage inflammatory response and VHL mutation status on the development of clear cell renal carcinoma. Chan-Yen Kuo, Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan, New Taipei City, Taiwan (Greater China).

B032 Defining cancer stem cells and their vulnerabilities in renal cell carcinoma. Yasser Riazalhosseini, Department of Human Genetics, McGill University, McGill Genome Center, MontrealQuebec, Canada.

B033 Targeting acquired resistance to HIF2a inhibition in kidney cancer. Fangzhou Zhao, UT Southwestern Medical Center, Dallas, Texas.